These challenges may foster abbreviated evaluations, with some clinicians prematurely diagnosing “unexplained chronic cough” and “refractory chronic cough” in patients who have not been ...

Adults with refractory chronic cough who received twice-daily camlipixant had decreases in cough frequency and better scores ...

The most common causes of chronic cough include gastroesophageal reflux disease (GERD), asthma, and postnasal drip (also ...

At the moment there are no approved therapies for suppressing refractory chronic cough, defined as lasting for eight weeks or more, which is estimated to affect somewhere between 5% and 10% of ...

Shorthand for ‘Refractory Chronic Cough Improvement Via Nalbuphine ER’, the River trial saw patients dosed with Haduvio for 21 days followed by a 21-day washout period. Patients received ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal ...

Refractory chronic cough, affecting approximately 2-3 million individuals in the U.S., is persistent and remains untreated as no therapies are approved, causing serious complications and economic ...

Haduvio reduced 24-hour cough frequency by 67% from baseline and 57% vs. placebo in Trevi's Phase 2a trial for refractory chronic cough. 84% of Haduvio patients saw at least a 30% cough reduction vs.

Trevi Therapeutics’ stock value has shot up more than 53% after its investigational therapy Haduvio (nalbuphine hydrochloride ...